Metformin and AGIs show potential for improved outcomes in COVID-19 patients with type 2 diabetes

james-yarema-kdgiNc0sDeI-unsplash

A new study has found a significant association between metformin and AGI use and reduced all-cause mortality in COVID-19 patients with Type 2 diabetes. Conversely, insulin use was linked to an increased risk of death.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE